MedTrace Logo

Nilotinib in the Treatment of Systemic Sclerosis

NCT01166139 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-10-04

Study results available
· View outcomes & findings →

Summary

A phase IIa open-label single center pilot study to assess the safety and efficacy of Nilotinib in patients with Scleroderma.

Conditions

Interventions

DRUG

Nilotinib (Tasigna)

Patients will be treated with Nilotinib 400 mg two times a day for 6 months.

Sponsors & Collaborators

  • Rudolph Rupert Scleroderma Program

    collaborator UNKNOWN

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • Hospital for Special Surgery, New York

    lead OTHER

Principal Investigators

  • Robert Spiera, MD · Hospital for Special Surgery, New York

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-07-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01166139 on ClinicalTrials.gov